Zepbound Safety Guide

Zepbound side effects: what the data actually shows

By Iacob Pastina · Independent Researcher · Updated May 2026

The most common Zepbound side effects are gastrointestinal: nausea (33%), diarrhea (25%), constipation (20%), and vomiting (12%). 98% of GI side effects in the SURMOUNT-1 trial were mild to moderate, peaked during the 24-week dose escalation, and improved over time. Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist — its dual mechanism produces higher weight loss than Wegovy (20.9% vs 14.9% at maintenance dose) but a longer 24-week titration. All percentages below come from the FDA-approved Zepbound prescribing information.

Choosing between Zepbound and Wegovy? See our Wegovy vs Zepbound 2026 head-to-head for cost, effectiveness, and side-effect comparison. Or read the Wegovy side effects deep dive if you're weighing both options.

Call your doctor or 911 immediately if you experience:

• Severe upper abdominal pain radiating to the back (possible pancreatitis — call 911)
• Difficulty breathing, throat swelling, or widespread hives (call 911)
• Inability to keep fluids down for 24+ hours (kidney-injury risk — call your provider or ER)
• Sharp upper-right pain after fatty meals with fever or jaundice (gallbladder — provider call)
• New or worsening suicidal thoughts (call your provider AND 988)

Report any serious adverse event to FDA MedWatch.

Common side effects: rates from the Zepbound label

Source: FDA-approved prescribing information for Zepbound (tirzepatide 2.5mg–15mg), based on the SURMOUNT-1 trial published in NEJM (2022).

Side effect	Rate	Severity	When it peaks
Nausea	33%	Mild to moderate	Weeks 4-12 (during dose escalation)
Diarrhea	25%	Mild to moderate	Weeks 1-12
Constipation	20%	Mild	Weeks 4-20 (worsens as appetite drops)
Abdominal pain	18%	Mild cramping (severe pain is a red flag)	Weeks 1-8
Vomiting	12%	Mild to moderate	Weeks 4-12
Injection site reactions	8%	Mild — redness, itching, mild swelling	First 24 hours after injection
Headache	13%	Mild	Weeks 1-4
Fatigue	8%	Mild	Weeks 1-8
Dyspepsia (indigestion)	9%	Mild	Throughout treatment
Hair loss (telogen effluvium)	6%	Cosmetic — temporary	Months 3-6 (related to rapid weight loss, not the drug directly — note this is 2× Wegovy's rate)

What to expect, week by week

Zepbound uses a 24-week dose-escalation schedule from 2.5mg starter to the maintenance dose of 15mg, stepping every 4 weeks. The longer titration (vs Wegovy's 16 weeks) tends to reduce peak GI symptoms but extends the side-effect window.

Weeks 1-4 (2.5mg starter)

What's typical: Mild nausea (10-15% of patients), occasional appetite reduction starts. Most users tolerate the starter dose well — it's intentionally sub-therapeutic to let the gut adjust.

Red flags: Persistent vomiting, severe abdominal pain, allergic reaction symptoms.

Weeks 5-8 (5mg therapeutic minimum)

What's typical: First therapeutic dose. Nausea picks up (15-25% baseline). Appetite suppression more noticeable. SURMOUNT-1 showed measurable weight loss begins here.

Red flags: Inability to keep fluids down for 24+ hours, severe upper abdominal pain radiating to back, fever.

Weeks 9-12 (7.5mg)

What's typical: GI symptoms commonly peak. Constipation more common as caloric intake drops. By week 12 most users have lost 5-8% of baseline body weight.

Red flags: Worsening symptoms instead of improving — discuss dose-hold with your provider before escalating to 10mg.

Weeks 13-16 (10mg)

What's typical: Many users plateau briefly during this transition. GI symptoms typically stabilizing. Hair shedding (telogen effluvium) may begin around month 3-4 in some users.

Red flags: New or worsening upper-right abdominal pain (gallbladder), severe fatigue with low urine output (kidney).

Weeks 17-20 (12.5mg)

What's typical: Continued weight loss, GI side effects diminishing for most users. Some patients stop here if results are sufficient and tolerance is good — 12.5mg is a clinically valid maintenance dose.

Red flags: Severe hair shedding interfering with quality of life — review protein intake (60-80g/day target) and iron/biotin levels.

Weeks 21-24+ (15mg maintenance)

What's typical: Highest approved dose. SURMOUNT-1 showed 20.9% average weight loss at 72 weeks at this dose. GI symptoms minimal for most users by this point.

Red flags: Any new symptom that emerges months into treatment warrants a provider call — late-onset pancreatitis and gallbladder issues do occur, especially given Zepbound's higher weight loss rate.

Management protocols for the most common side effects

Nausea (33% of patients)

• Eat smaller, more frequent meals (5-6 small instead of 3 large)
• Avoid fatty, fried, spicy, or highly aromatic foods during dose escalation
• Stay hydrated with small sips throughout the day; ginger or peppermint tea helps many users
• Take Zepbound on the same day each week — many providers suggest a Friday or Saturday so peak effects fall on a low-stress weekend
• Most providers will hold dose escalation for 4 additional weeks if nausea is intolerable rather than push to the next dose. Zepbound's 6 dose levels give more flexibility than Wegovy's 5.

Constipation (20%) — Zepbound's most under-discussed side effect

• Increase fiber gradually (25-30g/day) — too much too fast worsens GI symptoms
• Drink at least 64oz of water daily, more if active
• Walking 30 minutes daily helps gut motility
• OTC stool softeners (docusate) are safe for short-term use; check with provider before laxatives
• Persistent constipation past 1 week with abdominal distension warrants a provider call
• Note: Zepbound's constipation rate (20%) is lower than Wegovy's (24%) but persists longer because the 24-week titration extends the window when caloric intake drops

Diarrhea (25%) and Vomiting (12%)

• Maintain hydration as the priority — water plus electrolytes (sports drinks, oral rehydration salts)
• BRAT diet (bananas, rice, applesauce, toast) for diarrhea
• Avoid caffeine, alcohol, and dairy during acute symptoms
• If you cannot keep fluids down for 24 hours, call your provider — risk of dehydration-induced kidney injury
• Zepbound vomiting rate (12%) is half of Wegovy's (24%) — if you're struggling more than expected, a dose-hold is reasonable

Hair shedding (6%) — 2× Wegovy's rate

• Zepbound produces more rapid weight loss (20.9% vs 14.9%), and faster loss = more telogen effluvium
• This is the body's response to rapid weight change, not the drug acting on hair follicles directly
• Ensure 60-80g/day of protein intake (this is harder than it sounds when appetite is suppressed)
• Test ferritin (iron storage), vitamin D, and biotin BEFORE supplementing — random supplementation can mask deficiencies
• Regrowth typically begins 3-6 months after weight stabilizes. Plan for the long tail.

Injection site reactions (8%)

• Rotate injection sites between abdomen, thigh, and upper arm — never inject in the same spot twice in a row
• Allow the pen to reach room temperature before injecting (15-30 min out of fridge)
• Mild redness or itching for 24 hours is normal; persistent welts or spreading rash warrant a provider call
• If a reaction recurs at every site, talk to your provider about technique review or potential hypersensitivity

Serious side effects — recognize these red flags

Rare but serious. Knowing the warning signs is the difference between a manageable problem and an emergency. Note: Zepbound's gallbladder risk is slightly elevated vs Wegovy because rapid weight loss is the primary driver of gallstones, and Zepbound produces more loss.

Pancreatitis

<0.5% (rare but serious)

Red-flag symptoms: Severe upper abdominal pain radiating to the back, with persistent nausea or vomiting

Action: STOP Zepbound and seek emergency care immediately. Do not restart without provider clearance.

Gallbladder problems

0.6% (gallstones), 0.2% (cholecystitis)

Red-flag symptoms: Sharp upper-right abdominal pain after fatty meals, fever, jaundice. Rapid weight loss is the primary risk factor — Zepbound's higher loss rate (20.9%) means this risk is real for some patients.

Action: Contact your provider for imaging. May require surgical removal in 0.3-0.6% of cases.

Kidney injury (acute)

Rare

Red-flag symptoms: Decreased urine output, swelling, fatigue — usually after persistent vomiting or diarrhea causing dehydration

Action: Maintain aggressive hydration during GI symptoms. If you cannot keep fluids down for 24 hours, contact your provider or ER.

Hypoglycemia

Variable — primarily in patients also taking insulin or sulfonylureas

Red-flag symptoms: Shakiness, sweating, confusion, rapid heartbeat, blurred vision

Action: Treat immediately with 15g fast-acting carbs (juice, glucose tablets). Recheck in 15 minutes. Discuss insulin/sulfonylurea dose reduction with your prescriber if recurring.

Severe allergic reaction (anaphylaxis)

Rare (<0.1%)

Red-flag symptoms: Difficulty breathing, throat or facial swelling, widespread hives, drop in blood pressure

Action: CALL 911. Do not drive yourself.

Suicidal ideation

Under FDA post-marketing review — no causal link established

Red-flag symptoms: New or worsening depression, mood changes, self-harm thoughts

Action: Contact your provider AND report to FDA MedWatch (1-800-FDA-1088). The 988 Suicide & Crisis Lifeline is available 24/7.

The boxed warning: thyroid C-cell tumors

Zepbound carries a boxed warning— the FDA's strongest warning level — for thyroid C-cell tumors. This is based on rodent studies; no causal link has been established in humans.

Zepbound is contraindicated in patients with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Your prescriber should screen for these before initiating Zepbound. If a telehealth provider does not ask about thyroid history during intake, treat that as a quality flag — programs with stronger clinical oversight (board-certified obesity medicine physicians, comprehensive intake) catch this systematically.

Choosing a provider who handles Zepbound's 24-week titration well

Zepbound's longer 24-week ramp matters more than Wegovy's 16-week ramp when picking a provider. You'll be in the side-effect-prone phase for 6 months. Programs that include regular check-ins, willingness to hold dose escalation, and quarterly labs to catch issues early earn their price during this stretch.

Among the 48 GLP-1 telehealth providers we track, Eden Health (8.9/10) is our highest-rated for medical oversight: board-certified obesity medicine physicians, quarterly blood panels included, and a published protocol for dose-hold during intolerable side effects. For comprehensive support across Zepbound's 24-week titration, this matters more than the price difference between programs.

See how all 48 providers score on clinical oversight in the full rankings, or take the 60-second match quiz to find providers that fit your support needs.

Wegovy side effects deep dive — for users comparing the two
Wegovy vs Zepbound: cost, side effects, and weight loss
Cross-drug GLP-1 side effects comparison — Wegovy vs Zepbound vs Foundayo vs Rybelsus rates side-by-side
FDA warning letter tracker — 50+ enforcement actions against GLP-1 providers since 2025
Provider safety checker — verify any GLP-1 telehealth program before enrolling

Sources

This page is for informational purposes only and is not medical advice. Always discuss medication decisions with a licensed prescriber. Side-effect rates are population averages from clinical trials and may not reflect your individual experience. If you are experiencing a medical emergency, call 911.